0
Viewpoint |

Unintended Consequences of Regulatory Initiatives in Childhood Cancer Drug Development

Peter C. Adamson, MD1
[+] Author Affiliations
1Division of Clinical Pharmacology and Therapeutics, The Children’s Hospital of Philadelphia, Pennsylvania
JAMA Pediatr. 2013;167(10):886-887. doi:10.1001/jamapediatrics.2013.2488.
Text Size: A A A
Published online

Extract

Prior to 1997, and almost 30 years after Shirkey’s editorial1 that coined the phrase “therapeutic orphan,” the legislative and regulatory efforts to address the issue of labeling medications for the safe and effective use by children were, by and large, unsuccessful. With an estimated 75% of the drugs marketed in the United States lacking essential pediatric data,2 it would take a new legislative effort, first proposed in 1994 by Senator Nancy Kassebaum of Kansas, that incorporated both an incentive and a requirement for industry to conduct appropriate pediatric studies. In 1997, the Food and Drug Administration Modernization Act (FDAMA), which provided an additional 6 months of marketing exclusivity to industry as incentive, was signed into law, catalyzing the development and conduct of a range of pediatric clinical investigations.3 The FDAMA, the incentive, coupled with the Pediatric Final Rule, the requirement, were subsequently replaced by the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), now in place for a decade. The Institute of Medicine’s 2012 report on the studies conducted under BPCA and PREA found that important information to guide clinical care for children was emerging from these studies, and noted a trend in improvement in the quality of studies and reporting of results over time.4

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
Jobs
brightcove.createExperiences();